Drugs /

relacorilant

Back to Drugs List

Overview

NCI Definition [1]:
An orally available antagonist of the glucocorticoid receptor (GR), with potential antineoplastic activity. Upon administration, CORT125134 competitively binds to and blocks GRs. This inhibits the activity of GRs, and prevents both the translocation of the ligand-GR complexes to the nucleus and gene expression of GR-associated genes. This decreases the negative effects that result from excess levels of endogenous glucocorticoids, like those seen when tumors overproduce glucocorticoids. In addition, by binding to GRs and preventing their activity, inhibition with CORT125134 also inhibits the proliferation of GR-overexpressing cancer cells. GRs are overexpressed in certain tumor cell types and promote tumor cell proliferation.

Clinical Trials

View Clinical Trials for relacorilant

Relacorilant has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating relacorilant, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 3 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for relacorilant clinical trials.

Adrenal cortex carcinoma, breast carcinoma, and malignant solid tumor are the most common diseases being investigated in relacorilant clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Relacorilant
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Relacorilant
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating relacorilant and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cort-125134, glucocorticoid receptor antagonist cort125134, cort125134
NCIT ID [1]:
C127838

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.